DihexavsDSIP

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a modified hexapeptide derivative of angiotensin IV developed at Washington State University by Dr. Joseph Harding's laboratory. It was designed to mimic the cognitive-enhancing effects of angiotensin IV and its analogue Nle1-AngIV (DIIIA), which had shown procognitive properties but required central administration. Dihexa was engineered with metabolic stability modifications (hexanoic acid modifications at both termini) for oral bioavailability and blood-brain barrier penetration.

Dihexa's mechanism centers on the hepatocyte growth factor (HGF)/c-Met receptor system, which plays a critical role in brain development, neuroplasticity, and neuroprotection. Dihexa acts as an allosteric modulator and potentiator of HGF signaling — it facilitates HGF dimerization and binding to the c-Met receptor tyrosine kinase, amplifying the downstream signaling cascade. Activated c-Met triggers the PI3K/Akt pathway (neuronal survival), the Ras/MAPK/ERK pathway (synaptic plasticity and gene expression), and the Rac1/Cdc42 pathway (cytoskeletal remodeling for dendritic spine formation).

The cognitive effects stem from enhanced dendritic spine formation and synaptic connectivity in the hippocampus — the brain region critical for learning and memory. Dendritic spines are the postsynaptic structures where most excitatory synapses form, and their density and morphology are directly correlated with cognitive function. Dihexa treatment in animal models increased spine density, enhanced long-term potentiation (LTP — the cellular correlate of memory formation), and restored cognitive function in models of dementia. The reported potency — up to 10 million times more potent than BDNF in promoting synaptic connectivity in cell culture assays — is striking but should be interpreted cautiously, as in vitro potency does not always translate to in vivo efficacy. The activation of the HGF/c-Met pathway raises theoretical concerns about tumor promotion, as this pathway is frequently co-opted in cancer for metastasis and angiogenesis, and no human safety data exists to evaluate this risk.

Delta Sleep-Inducing Peptide is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit cerebral venous blood during electrically induced sleep in 1977. Despite decades of research, its precise molecular receptor has not been definitively identified, making DSIP unusual among well-studied peptides. However, its physiological effects have been extensively characterized.

DSIP's sleep-promoting mechanism involves modulation of the balance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission in sleep-regulating brain regions. It enhances GABAergic tone in the ventrolateral preoptic area (VLPO) — the brain's primary sleep-promoting nucleus — while reducing glutamatergic excitatory drive in wake-promoting areas like the lateral hypothalamus and locus coeruleus. The net effect is promotion of slow-wave (delta) sleep, characterized by high-amplitude, low-frequency (0.5-4 Hz) EEG oscillations. This is the deepest, most restorative sleep stage, during which growth hormone secretion peaks, memory consolidation occurs, and cellular repair processes are most active.

Beyond sleep, DSIP has significant neuroendocrine effects. It reduces cortisol secretion by suppressing corticotropin-releasing hormone (CRH) and ACTH release, lowering the activity of the hypothalamic-pituitary-adrenal (HPA) stress axis. This stress-reducing effect may itself contribute to sleep quality, as HPA axis hyperactivity is a common cause of insomnia and fragmented sleep. DSIP also modulates endogenous opioid signaling — it has been studied in opiate withdrawal protocols for its ability to normalize disturbed endorphin/enkephalin balance. Some research suggests it may regulate somatostatin release and interact with the orexin/hypocretin system, though these mechanisms are less well established. The paradox of DSIP is that despite its very short plasma half-life (15-25 minutes), sleep-promoting effects persist for hours, suggesting it triggers sustained changes in neural network activity or gene expression rather than requiring continuous receptor occupancy.